Press Release


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Spectrum Pharmaceuticals Highlights Five Abstracts of Clinical Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 29-June 2, 2015

May 29, 2015 at 7:00 AM EDT

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced presentations of clinical data for Beleodaq® (belinostat), Folotyn® (pralatrexate injection) and Poziotinib to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, from May 29 to June 2, 2015.

For more information about the ASCO Annual Meeting and for a complete list of abstracts, please refer to the conference Web site at

Sunday, May 31, 2015, 8:00 AM-11:30 AM CDT (Poster) and 4:30 PM-5:45 PM CDT (Poster Discussion)

Abstract #   Type   Title   First Author   Location
10516 Poster A Phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS). Joanna Vitfell-Rasmussen S Hall A
e13581 Electronic UGT1A1 genotype effects on PK, PD and toxicities of belinostat administered by 48 h continuous infusion. Andrew K.L Goey Electronic
e18564 Electronic Effect of treatment on the regression and growth rates of thymic epithelial tumors (TETs).

Mauricio Emmanuel

Burotto Pichun


Monday, June 1, 2015, 8:00 AM-11:30 AM CDT

Abstract # Type Title First Author Location
8085 Poster A Phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Ji-Youn Han S Hall A
E15037 Electronic A Phase II trial of pralatrexate (P) plus oxaliplatin (O) in advanced esophago-gastric cancer (aEGC): survival analysis and pharmacogenetic correlates. Usha Malhotra Electronic

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum markets five hematology/oncology drugs, and expects an FDA decision on another hematology drug later this year. Additionally, Spectrum's pipeline includes three drugs targeting blockbuster markets in advanced stages of clinical development. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at

Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.®, FUSILEV®, FOLOTYN®, ZEVALIN®, MARQIBO®, and BELEODAQ® are registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliates. REDEFINING CANCER CARE™, EVOMELA™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2015 Spectrum Pharmaceuticals, Inc. All Rights Reserved

Spectrum Pharmaceuticals, Inc.
Shiv Kapoor
Vice President, Strategic Planning & Investor Relations

Source: Spectrum Pharmaceuticals, Inc.

News Provided by Acquire Media